AJHG提供了關于人類遺傳、遺傳原理在醫學和公共政策中的應用以及分子和細胞生物學相關領域的研究和綜述的記錄。AJHG探索的主題包括行為遺傳學、生物化學遺傳學、臨床遺傳學、細胞遺傳學、畸形學、基因治療、遺傳咨詢、遺傳流行病學、基因組學、免疫遺傳學、分子遺傳學、神經遺傳學和群體遺傳學。AJHG歡迎提交關于人類遺傳學各方面及時主題的文章和報告，包括與人類遺傳學直接相關的模型生物體的研究。手稿應該以一種讓代表人類遺傳學不同背景的研究人員能夠理解的方式來寫。歡迎介紹遺傳學界普遍感興趣的新統計方法。新方法應該與現有方法進行比較，使用真實數據和/或基于真實數據示例的參數(例如，單倍型頻率、效果大小)進行模擬(例如，來自HapMap項目的標記或單倍型數據)。所有小說的計算機程序必須在手稿出版前公開，并且手稿的Web資源部分必須包含網站的URL。也歡迎來信評論以前在AJHG上發表的材料。AJHG不發表關于單個突變的報告，也不發表對先前確定基因座的突變調查報告，除非它們具有不尋常的意義和實質性的見解。只有在特別感興趣的情況下，才會考慮對新鏈接分配的說明。負面數據的報告通常不予考慮。

AJHG provides a record of research and review relating to heredity in humans and to the application of genetic principles in medicine and public policy, as well as in related areas of molecular and cell biology. Topics explored by AJHG include behavioral genetics, biochemical genetics, clinical genetics, cytogenetics, dysmorphology, gene therapy, genetic counseling, genetic epidemiology, genomics, immunogenetics, molecular genetics, neurogenetics, and population genetics.AJHG welcomes submissions of articles and reports on timely subjects concerning all aspects of human genetics, including studies of model organisms that are of direct relevance to human genetics. Manuscripts should be written in a manner accessible to investigators representing diverse backgrounds in human genetics. Descriptions of new statistical methods of general interest to the genetics community are welcome. New methods should be compared to existing methods with the use of real data and/or simulations with parameters (e.g., haplotype frequencies, effect sizes) that are based on a real data example (e.g., marker or haplotype data from the HapMap project). All novel computer programs must be made publicly available by the time that the manuscript is published, and a URL for the website must be included in the Web Resources section of the manuscript. Letters commenting on material previously published in AJHG are also welcome.AJHG does not publish reports of either single mutations or mutational surveys of previously identified loci unless they have unusual significance and substantial insight. Descriptions of new linkage assignments will be considered only if they are of special interest. Reports of negative data will not normally be considered.